Table 4.

Most relevant evidence about the potential value of miRNA in PtR OC.

Author, Year	Material and Methods	Results	Conclusions
Benson EA. 2015 [106]	14 pts with PtR ROC Evaluation of plasma miRNAs in predicting the response to carboplatin and decitabine	10 miRNAs changed in concentration at the end of the first cycle of treatment (ranging from 2.9 to 4, p < 0.05) and were associated with response. Lower concentrations miR-148b-5p predicted worse PFS (p = 0.015).	miRNA analysis predicts the response to chemotherapy and prognosis.
Vigneron N. 2020 [107]	35 pts with ROC (16.9% PtR) Evaluation of miR-622 levels at relapse Classification according to Levels: >0.34 zmol/mL vs. <0.34 zmol/mL	OS miRNA > 0.34 zmol/mL vs. <0.34 zmol/mL: 7.9 months vs. 20.6 months, HR 3.15, p = 0.006	miRNA analysis predicts prognosis

Abbreviations: miRNA micro Ribonucleic Acid, OS Overall Survival, PFS Progression-Free Survival, PtR Platinum-Resistant, Pts Patients, ROC Recurrent Ovarian Cancer.